A joint research team between the Center for Quantum Information and Quantum Biology (QIQB) at The University of Osaka and ...
Additional information about the 2026 AAN Annual Meeting is available at www.aan.com.
MEDIA ALERT]Flagship's early-stage companies to receive AWS cloud credits, technical support, and AI capabilities to ...
Phase 1b norovirus challenge study is underway at Emory University School of MedicineCDI-988 is the first oral antiviral ...
Chair, President, and CEO Sheila DeWitt, PhD, shares reflections and outlook on 15 Years of Drug Discovery and Four Landmark M&A Transactions BOSTON, March 31, 2026 /PRNewswire/ -- In honor of Women's ...
An international team of scientists proved the never-before-seen molecule's exotic nature using a quantum computer, ...
One-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and a favorable safety ...
A collaboration “across multiple therapeutic areas” could net the Hong Kong-based biotech more than $2 billion as Lilly seeks ...
The big pharma and AI drug developer expand on a partnership that launched with a 2023 software licensing accord.
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today ...
Eli Lilly signs AI-driven drug discovery deal with Insilico worth up to $2.75 billion. Agreement expands access to China’s fast-growing biotech innovation pipeline. Insilico shares jump as global ...
Fujitsu Limited and the Center for Quantum Information and Quantum Biology at The University of Osaka today announced the development of a new technology designed to accelerate the industrial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results